Statistics for DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
Total visits
| views | |
|---|---|
| DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma | 2 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:8a840ca1-cb73-42c8-83ad-8b2ed0c3ae1b | 24 |
| java.util.UUID:40d70a89-bbd9-47a5-a58a-a36e5efd4a82 | 14 |
| java.util.UUID:887571d9-4de8-4cad-8da7-354a00a2d440 | 9 |
| Prawitz2021Dreamm2-CCBYNC.pdf | 5 |
Top country views
| views | |
|---|---|
| United States | 2 |
Top city views
| views | |
|---|---|
| Bloomington | 2 |